Business
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
- sNDA submitted for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC)
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- sNDA submitted for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC)\n\n- Submission based on MARCH Phase 3 study with high statistical significance (p","length":366,"tagName":"div"}]